SORT BY

FILTER BY

also on other fortune lists

company facts

f500 stats

Fortune 500

Courtesy of Bristol-Meyers Squibb

147

Bristol-Myers Squibb

BMY

The biopharmaceutical company manufactures medicines for Alzheimer’s, dementia, pyschiatric disorders, cardiovascular, diabetes, oncology, and hepatitis.

Looking for leads, investment insights, or competitive intelligence?

CEO

Giovanni Caforio

CEO Title

Chief Executive Officer & Director

Sector

Health Care

Industry

Pharmaceuticals

HQ Location

New York, NY

Years on Fortune 500 List

23

Employees

25,000

Profile provided by S&P Global.
Key Financials (Last Fiscal Year)
$ millions% change
Revenues ($M)$19,42717.3%
Profits ($M)$4,457.0184.8%
Assets ($M)$33,707
Total Stockholder Equity ($M)$16,177
Market Value — as of March 31, 2017 ($M)$89,591
Profit Ratios
Profit as % of Revenues22.9%
Profits as % of Assets13.2%
Profits as % of Stockholder Equity27.6%
Earnings Per Share (Last Fiscal Year)
Earnings Per Share ($)2.65
EPS % Change (from 2015)184.9%
EPS % Change (5 year annual rate)4.2%
EPS % Change (10 year annual rate)12.6%
Total Return
Total Return to Investors (2016)-13.0%
Total Return to Investors (5 year, annualized)14.0%
Total Return to Investors (10 year, annualized)12.7%
STOCK QUOTE
()0.00 0.00 (0)
  • Previous Close:
  • Market Cap: NaNB
  • Next Earnings Date:
  • High:
  • Low:
  • 52 Week High:
  • 52 Week Low:
  • 52 Week Change %: 0.00
  • P/E Ratio: n/a
  • EPS:
  • Dividend Yield: n/a

News about Bristol-Myers Squibb

Merck's Bet on Cancer Immunotherapy Is Paying Off in Spades and Helping Lung Cancer Patients Live Longer

A combination of Merck's Keytruda and chemotherapy cut lung cancer death rates in half.

Read More →
Why Cancer Drug Maker Incyte's Stock Plunged—And Took Others Down With It

Drug giants Merck and Bristol-Myers Squibb felt the pain, too.

Read More →
This New Drug Combination Doubles the Chance of Keeping Lung Cancer at Bay

The finding could result in annual sales of $4.6 billion by 2023.

Read More →
Supreme Court Ruling Could Save J&J Millions in Talc Cancer Lawsuits

The ruling led a St. Louis judge at J&J's urging to declare a mistrial in the latest talc case.

Read More →